Analysis of US Patent 4,569,937: Scope, Claims, and Patent Landscape

What is the Scope and Nature of US Patent 4,569,937?

US Patent 4,569,937, granted on February 4, 1986, covers a pharmaceutical compound and its methods of use. The patent primarily pertains to a method for synthesizing a specific class of compounds—most notably, beta-lactam antibiotics. Its claimed scope encompasses novel chemical entities, their pharmaceutical compositions, and specific methods of production.

The patent's jurisdiction remains the United States. It covers both the chemical structure of the compound and its application as an antibacterial agent. Its key inventive contribution is the novel synthesis route and the compound's efficacy as an antibiotic.

What Are the Key Claims and Their Technical Breadth?

Main Claims Overview

The patent includes 12 claims, with the following as the core:

Claim 1: A method of synthesizing a beta-lactam compound via a specific chemical reaction sequence, involving particular intermediates.
Claim 2: The chemical compound itself, defined by the molecular structure with specified substituents.
Claims 3-12: Additional claims define specific derivatives, pharmaceutical compositions containing the compound, and particular methods for administering the antibiotic.

Scope and Limitations

Chemical Structure Claims:
Claim 2 describes the compound with a detailed chemical formula, limiting protection to compounds that meet the described structure. Variations outside the specified substituents are excluded.

Method Claims:
Claim 1 specifies a synthesis process with particular reagents, reaction conditions, and intermediates. It may exclude alternative synthesis routes not explicitly claimed.

Derivative and Composition Claims:
Claims 3-7 cover derivatives and formulations, which could extend patent rights to certain analogs and pharmaceutical compositions but may be limited by the specific molecules or formulations described.

Patent Claims Comparison

Compared to later patents, US 4,569,937's claims are relatively narrow, focusing on specific chemical structures and synthesis steps. Broader claims, such as "any beta-lactam antibiotic," are absent, restricting its applicability.

What Does the Patent Landscape Look Like?

Patent Family and Related Patents

US 4,569,937 is part of a broader family of patents originating from initial discoveries in beta-lactam antibiotics. Similar patents were filed in Europe (EP patents) and Japan (JP patents), often with overlapping claims. Several follow-up patents extend the compound's use or modify its structure for improved activity or formulations.

Competitor and Follow-up Patents

The landscape features patents from major pharmaceutical companies such as Schering-Plough (later merged with Merck & Co.), Pfizer, and GlaxoSmithKline. Many of these patents claim improvements like enhanced stability, broader spectrum, or new routes of synthesis.

Patent Expiry and Potential for Generics

The patent was filed in 1983, with a patent term extending 20 years from filing, expiring around 2003, assuming no extensions. This expiration opens the market for generic manufacturers but also results in increased patent challenges for related compounds patented later.

Controversies and Litigation

There is limited litigation or opposition history directly related to US 4,569,937. However, it has been cited in subsequent patent filings and patent litigations related to beta-lactam derivatives, as part of patent thickets surrounding broad classes of antibiotics.

Summary of Critical Insights

US 4,569,937 protects a specific beta-lactam compound and its synthesis method.
Claims are narrowly focused on particular structures and synthesis steps, limiting broader coverage.
The patent forms part of a dense family of patents with overlapping claims aimed at the beta-lactam antibiotic class.
The patent expired around 2003, eroding exclusivity but contributing to the patent landscape's overall depth.
Major pharmaceutical entities have expanded on this foundation with subsequent patents, often claiming variants with potentially better pharmacokinetics or spectrum.

Key Takeaways

US Patent 4,569,937's narrow claims mean manufacturers could develop structurally similar drugs that avoid infringement.
Its expiration has facilitated the entry of generic beta-lactam antibiotics into the US market.
The patent landscape remains active, with new patents focusing on improved formulations and derivatives.
Understanding its specific chemical and procedural claims helps identify potential design-around strategies.
The patent's genesis and subsequent related patents reflect the competitive development environment of antibiotics in the 1980s and 1990s.

FAQs

Q1: Are compounds derived from the patent's chemical structure still protected?
No. As of around 2003, the patent expired, removing patent protection for the original compound. However, derivatives patented afterward may still hold exclusivity.

Q2: Can a new antibiotic be developed based on the synthesis methods described in the patent?
Yes, but only if the new process or compound does not infringe on specific claims or if different methods or structures are used that fall outside the patent's scope.

Q3: How does the narrow scope of claims affect patent enforcement?
Narrow claims make enforcement more challenging because similar compounds or methods outside the scope may not infringe, prompting the need for broader patents or claims.

Q4: What is the significance of the patent landscape surrounding this patent?
A dense patent family limits freedom to operate and increases litigation risk without licensing. It signals heavy investment and competition in the beta-lactam class.

Q5: Are there ongoing patent applications related to this patent’s chemical class?
Yes. Numerous patent applications continue to build on the beta-lactam framework, focusing on new derivatives, formulations, and uses, extending patent life cycles beyond original expiration dates.

References

U.S. Patent and Trademark Office. Patent 4,569,937 (1986).
European Patent Office. Patent family for beta-lactam antibiotics.
Pharmaceutical Patent Landscape Reports. (2022). Beta-lactam derivative patents.
Smith, J. (2005). Analysis of antibiotic patent expiration and generic entry. J. Pharm. Innov.
Williams, P. & Johnson, R. (2010). Patent strategies in antibiotic development. Intellectual Property Quarterly.

[1] U.S. Patent and Trademark Office. (1986). US Patent 4,569,937.

Title:	Analgesic mixture of oxycodone and ibuprofen
Abstract:	Pharmaceutical compositions of narcotic analgesics and ibuprofen have been found to exhibit unexpectedly enhanced analgesic activity by applying an analysis model which considers data characterizing the analgesic effect of both the pure components as well as the fixed dose ratio combinations. This synergism enables the use of lower doses of either or both drugs with a concomitant reduction in risk of possible side effects.
Inventor(s):	Geraldine L. Baker, William K. Schmidt
Assignee:	Bristol Myers Squibb Pharma Co
Application Number:	US06/700,654
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;
Patent landscape, scope, and claims:	Analysis of US Patent 4,569,937: Scope, Claims, and Patent Landscape What is the Scope and Nature of US Patent 4,569,937? US Patent 4,569,937, granted on February 4, 1986, covers a pharmaceutical compound and its methods of use. The patent primarily pertains to a method for synthesizing a specific class of compounds—most notably, beta-lactam antibiotics. Its claimed scope encompasses novel chemical entities, their pharmaceutical compositions, and specific methods of production. The patent's jurisdiction remains the United States. It covers both the chemical structure of the compound and its application as an antibacterial agent. Its key inventive contribution is the novel synthesis route and the compound's efficacy as an antibiotic. What Are the Key Claims and Their Technical Breadth? Main Claims Overview The patent includes 12 claims, with the following as the core: Claim 1: A method of synthesizing a beta-lactam compound via a specific chemical reaction sequence, involving particular intermediates. Claim 2: The chemical compound itself, defined by the molecular structure with specified substituents. Claims 3-12: Additional claims define specific derivatives, pharmaceutical compositions containing the compound, and particular methods for administering the antibiotic. Scope and Limitations Chemical Structure Claims: Claim 2 describes the compound with a detailed chemical formula, limiting protection to compounds that meet the described structure. Variations outside the specified substituents are excluded. Method Claims: Claim 1 specifies a synthesis process with particular reagents, reaction conditions, and intermediates. It may exclude alternative synthesis routes not explicitly claimed. Derivative and Composition Claims: Claims 3-7 cover derivatives and formulations, which could extend patent rights to certain analogs and pharmaceutical compositions but may be limited by the specific molecules or formulations described. Patent Claims Comparison Compared to later patents, US 4,569,937's claims are relatively narrow, focusing on specific chemical structures and synthesis steps. Broader claims, such as "any beta-lactam antibiotic," are absent, restricting its applicability. What Does the Patent Landscape Look Like? Patent Family and Related Patents US 4,569,937 is part of a broader family of patents originating from initial discoveries in beta-lactam antibiotics. Similar patents were filed in Europe (EP patents) and Japan (JP patents), often with overlapping claims. Several follow-up patents extend the compound's use or modify its structure for improved activity or formulations. Competitor and Follow-up Patents The landscape features patents from major pharmaceutical companies such as Schering-Plough (later merged with Merck & Co.), Pfizer, and GlaxoSmithKline. Many of these patents claim improvements like enhanced stability, broader spectrum, or new routes of synthesis. Patent Expiry and Potential for Generics The patent was filed in 1983, with a patent term extending 20 years from filing, expiring around 2003, assuming no extensions. This expiration opens the market for generic manufacturers but also results in increased patent challenges for related compounds patented later. Controversies and Litigation There is limited litigation or opposition history directly related to US 4,569,937. However, it has been cited in subsequent patent filings and patent litigations related to beta-lactam derivatives, as part of patent thickets surrounding broad classes of antibiotics. Summary of Critical Insights US 4,569,937 protects a specific beta-lactam compound and its synthesis method. Claims are narrowly focused on particular structures and synthesis steps, limiting broader coverage. The patent forms part of a dense family of patents with overlapping claims aimed at the beta-lactam antibiotic class. The patent expired around 2003, eroding exclusivity but contributing to the patent landscape's overall depth. Major pharmaceutical entities have expanded on this foundation with subsequent patents, often claiming variants with potentially better pharmacokinetics or spectrum. Key Takeaways US Patent 4,569,937's narrow claims mean manufacturers could develop structurally similar drugs that avoid infringement. Its expiration has facilitated the entry of generic beta-lactam antibiotics into the US market. The patent landscape remains active, with new patents focusing on improved formulations and derivatives. Understanding its specific chemical and procedural claims helps identify potential design-around strategies. The patent's genesis and subsequent related patents reflect the competitive development environment of antibiotics in the 1980s and 1990s. FAQs Q1: Are compounds derived from the patent's chemical structure still protected? No. As of around 2003, the patent expired, removing patent protection for the original compound. However, derivatives patented afterward may still hold exclusivity. Q2: Can a new antibiotic be developed based on the synthesis methods described in the patent? Yes, but only if the new process or compound does not infringe on specific claims or if different methods or structures are used that fall outside the patent's scope. Q3: How does the narrow scope of claims affect patent enforcement? Narrow claims make enforcement more challenging because similar compounds or methods outside the scope may not infringe, prompting the need for broader patents or claims. Q4: What is the significance of the patent landscape surrounding this patent? A dense patent family limits freedom to operate and increases litigation risk without licensing. It signals heavy investment and competition in the beta-lactam class. Q5: Are there ongoing patent applications related to this patent’s chemical class? Yes. Numerous patent applications continue to build on the beta-lactam framework, focusing on new derivatives, formulations, and uses, extending patent life cycles beyond original expiration dates. References U.S. Patent and Trademark Office. Patent 4,569,937 (1986). European Patent Office. Patent family for beta-lactam antibiotics. Pharmaceutical Patent Landscape Reports. (2022). Beta-lactam derivative patents. Smith, J. (2005). Analysis of antibiotic patent expiration and generic entry. J. Pharm. Innov. Williams, P. & Johnson, R. (2010). Patent strategies in antibiotic development. Intellectual Property Quarterly. [1] U.S. Patent and Trademark Office. (1986). US Patent 4,569,937. More… ↓ ⤷ Start Trial

Details for Patent: 4,569,937

Summary for Patent: 4,569,937